Loading...
Loading...
MYNZ| Name | Value |
|---|---|
| Revenues | 373.2K |
| Cost of Revenue | 117.4K |
| Gross Profit | 255.8K |
| Operating Expense | 9,143.9K |
| Operating I/L | -8,888.1K |
| Other Income/Expense | -1,738.8K |
| Interest Income | 0.0K |
| Pretax | -10,626.9K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -10,626.9K |
Mainz Biomed B.V. is a molecular genetics cancer diagnostic company specializing in the development of in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. The company's product portfolio includes ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; and GenoStrip, a molecular genetic-based pathogen detection tool for environmental testing. Additionally, Mainz Biomed B.V. offers research-use-only and IVD tests, generating revenue through the sale of these diagnostic products and services.
